An interventional study of BD211 in β-thalassemia, sponsored by Shanghai BDgene Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-06-14.
Sponsored by Shanghai BDgene Co., Ltd. · Not applicable, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.
Among the 32 studies in Thalassemia with a site in China, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 21st registered.
252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.
Browse Thalassemia studies →12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:
ScinnoHub Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Rongrong Liu · Sites in China
Ages 18–75
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Sites in China
Ages 3–17
Rongrong Liu · Sites in China
Ages 3–20
Shenzhen Hemogen · Sites in China
Ages 6–35
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 33 across 171 interventional studies indexed under Thalassemia.
Median enrollment 30 across the 27 interventional studies, 30 across the 5 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 32 have an industry lead sponsor. The 10 most frequent:
Shanghai BDgene Co., Ltd. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Shanghai BDgene Co., Ltd. has 2 studies filed under Thalassemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Thalassemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06302491Kind Pharmaceuticals LLCA Study of Safety and Efficiency of AND017 in Patients With β-thalassemia | 2026-12 |
| NCT06465550Shanghai BDgene Co., Ltd.A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major | 2026-12 |
| NCT05851105Shenzhen Hemogenthe Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia | 2026-12-30 |
| NCT07725263Haikou Affiliated Hospital of Central South University Xiangya School of MedicineLow-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children | 2027-02-28 |
| NCT07579949ScinnoHub Pharmaceutical Co., Ltd.A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT) | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Thalassemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.
This is an open-label, single-dose study of BD211 in patients with transfusion-dependent β-thalassemia aged 3 to 18 years. It is estimated that 10 subjects will be enrolled. BD211 is a gene modified gene therapy product designed to produce healthy β-globin in red blood cells in beta-thalassemia patients. The total follow-up duration was 24 months, the safe endpoints and effectiveness endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent β-thalassemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ages 3 to 18 years old, including:
The parents or legal guardians must be able to understand and provide ICFs. If available, it is strongly recommended that children aged ≥8 years in treatment decisions and obtain written ICFs and be clearly documented; Diagnosed as Transfusion Dependent β-thalassemia with any genotype (β0, β+, βE/β0, βS/S, βS/β0, βS/β+), confirmed the analysis. No alfa chain genetic abnormalities. Subjects must stabilize and maintain an appropriate iron chelation regimen. Transfusion-dependent types are defined as requiring at least 100 mL/kg/ year of red blood cells (pRBCs).
Exclusion Criteria:
History of major organ injury including:
Liver disease, transaminase > 3 times the . (If the liver does not reveal evidence of widespread bridging fibrosis, cirrhosis, or acute hepatitis, this indicator will not be used as a criterion for the exclusion); Widely bridging fibrosis, histopathological evidence of acute hepatitis or cirrhosis showed in liver biopsy Heart disease, \< 25%; Kidney disease, \< 30% normal level; Of severe iron overload, confirmed by the study doctor; An heart MRI detection of T2 * \< 10 ms; Significant pulmonary hypertension needing clinical medical intervention.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10\^6 cells /kg \~ 10×10\^6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211
Genetic: BD211
Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
Percentage of treated participants with Transfusion-Dependent β-Thalassemia (TDT) who achieved transfusion independence (TI) for at least 6 months
TI defined as peripheral blood weighted average hemoglobin (Hb) \> or = 9 g/dL without packed red blood cell (pRBC) transfusion for 60 days after BD211 treatment, and transfusion is continuously halted for 12 months.
Time frame: 24 months
Hb (g/dL) level between 12 and 24 months after BD211 treatment compared with baseline Hb level
Hb (g/dL) in 12, 15, 18, 21 and 24 months after drug product infusion are tested and calculated.
Time frame: 24 months
Parameters of efficacy related to TI achievement after BD211 treatment
including a. Duration to achieve TI; b. Time from BD211 infusion to last transfusion; c. Time to reach TI from BD211 infusion; d. Mean weighted Hb (g/dL) during TI; and e. Proportion of patients achieving TI at 24 month after BD211 treatment.
Time frame: 24 months
Parameters of efficacy related to reduced blood transfusion after BD211 treatment
Including a. Using the transfusion volume from the 2 years prior to the participant's enrollment as a baseline, compared with the transfusion volume between 12 and 24 months after BD211 treatment (mL/kg/month, mL/kg/year), the proportion of participants categorized based on a reduction in transfusion volume of 50%, 75%, 90%, and 100%; b. Using the number of transfusions from the 2 years prior to the participant's enrollment as a baseline, comparing the changes in the volume of pRBC transfusions at 12 and 24 months after BD211 treatment; c. Using the transfusion requirement volume from the 2 years prior to the participant's enrollment as a baseline, comparing the changes in the pRBC transfusion requirement volume at 12 and 24 months after BD211 treatment.
Time frame: 24 months
Parameters of iron overload after BD211 treatment
Including a. Time from the last iron-chelation treatment to the last follow-up within 24 months; b. Decrease in serum ferritin level compared from baseline to 6 months and 12 months after BD211 infusion; c. Number and proportion of participants who did not require iron-chelation treatment for at least 6 months after BD211 infusion; d. Comparison of cardiac MRI T2 values at the end of the 24 month after BD211 treatment with the baseline values.
Time frame: 24 months
Parameters of growth and development after BD211 treatment
Percentage of pediatric participants reaching the standard for bone age, height, and weight at the same age, at baseline and 24 months after BD211 treatment.
Time frame: 24 months
Change in quality of life from baseline
Comparison of Pediatric Quality of Life Inventory (PedQL) scores in pediatric participants at 24 months after BD211 treatment with the scores at baseline.
Time frame: 24 months
Total hospitalizing days at 12, and 24 months (discharge after transplant)
Total hospitalizing days at 12, and 24 months after transplantation were counted.
Time frame: 24 months
Measurement of PD/PK parameters
Including a. The number and percentage of participants, in whom the HbAT87Q containing the βT87Q-globin remains at or above ≥2.0 g/dL for 6 months or longer, at 18 and 24 months after BD211 infusion; b. Average vector copy number (VCN) of the BD211 lentiviral vector in peripheral blood and bone marrow cells within 24 months after BD211 product infusion; c. Dose-response relationship within 24 months after BD211 infusion.
Time frame: 24 months
Neutrophil engraftment and platelet engraftment
Neutrophil engraftment was defined as the first of absolute neutrophil count (ANC) \> or = 0.5 ×10\^9/ L for 3 consecutive days (or 3 consecutive measurements done on separate days), after a post-transplant value less than (\<) 0.5 × 10\^9/L. Platelet engraftment was defined as the first of 3 consecutive platelet values \> or =20 × 10\^9/L for participants on different days with no platelet transfusionsadministered for 7 days immediately preceding. The day of engraftment is the first day of the 3 consecutive platelet measurements.
Time frame: 24 months
Transplant-related mortality in 3 months and 12 months
Transplant related mortality was definedas any death occurring in the study post drug product infusion deemed related to the transplant bythe investigator.
Time frame: 12 months
Overall survival
Overall survival was defined as time from date of BD211 Drug Product infusion (Day 1) to date of death. Overall survival was censored at the date of last visit if the participant was still alive.
Time frame: 24 months
RCL incidence
Subjects blood RCL was detected with specific assay method, and the incidence was calculated at different scheduled timeslots.
Time frame: 24 months
Characterized insertion mutagenesis events that lead to clonal dominance or leukemia
The number of insertion mutagenesis events that characterized clonal dominance or leukemia was collected.
Time frame: 24 months
Frequency and severity of AE
An AE was any untoward medical occurrence associated with the use of a drug in participants, whether or not considered drug related. An AE may include a change in physical signs, symptoms, and/or clinically significant laboratory change occurring in any phase of a clinical study.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Mar 2026, 30 months after the start.
Of 18 interventional studies with no phase under Thalassemia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 87. This study's planned 30 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai BDgene Co., Ltd.